1. Early Experience With Anterior Chamber Phakic IOL
Ahmed El-Massry M.D.
Professor of Ophthalmology
Alexandria University
Egypt
The author has no financial interest in the subject matter of this e-poster.
US Status: Investigational device limited by Federal Law to investigational use only

2. Refractive Options – Anterior Chamber (Angle Supported )
NuVita MA20 (B&L)
PMMA (IOL Tech)
ZSAL4 (Morcher)
NewLife (IOL Tech)
Kelman Duet (Tekia)
Vivarte (Ciba)
ICARE (Corneal)

3. Design Challenges Achieve low compression force
Gentle on delicate ocular tissues
Avoid pupil ovalization
Decrease inflammation
Maintain stability despite low compression force
Ensure low vault response as a function of compression
Critical for safe placement within anterior chamber
Facilitate reliable small incision surgery
Low inflammation and surgical induced astigmatism

4. Ideal Lens Position in vivo (no iridectomy/iridotomy required)
Optic
Iris
Crystalline
Lens
Footplate
2/3
1/3
Bridge
Anterior Chamber Ocular Coherence Tomography
*ZEISS is a registered trademarks of Carl Zeiss AG.

5. purpose
To evaluate the efficacy, stability , endothelial cell count, visual outcome , higher order aberration changes , IOP and lens position of one type of Phakic IOLs (Cachet produced by Alcon Laboratories) on six month period of follow up.

6. Methods A prospective non randomized single center study was done on:
- Twenty eyes of high myopes.
-That are eligible for anterior chamber phakic IOLs.
-Ranged from Diopters to Diopters.
-Anterior chamber depth is not less than 3.5mm.
-Endothelial cell count was not less than 2500 cells / mm2
-Age ranged from 26 to 33 years of age . In one eye opposite clear corneal incision was done to correct 1.0 Diopter of astigmatism.

7. Methods
All cases were operated under general anesthesia in Alex Eye Center in Alexandria, Egypt.
Phakic IOL (Cachet type of Alcon Laboratories) had been inserted for all the 20 eyes.
12 eyes for females and 8 were males
No intraoperative complication had been reported.

8. Results
Early results showed Uncorrected visual acuity of 0.8 to 1.0 on Snellen's chart in all eyes day 7 after surgery .
One eye had a spike of increased IOP six hours after surgery and had been controlled by oral Carbonic anhydrase inhibitor drug.
Six months follow up results of endothelial cell count , stability of the IOL, IOP showed non significant changes than preoperative data.

9. Conclusions
Early results show good visual outcome of the new phakic Cachet IOLs .
Longer period of follow up is needed to evaluate stability and endothelial cell count for this new lens .

10. Thank you